THE ASAN FOUNDATION;University of Ulsan Foundation For Industry Cooperation
发明人:
Jaekyoung SON,Jin Kyung RHO,Jae Cheol LEE
申请号：
US16274749
公开号：
US20200121645A1
申请日:
2019.02.13
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors.
